{
  "symbol": "VTGN",
  "company_name": "Vistagen Therapeutics Inc",
  "ir_website": "https://www.vistagen.com/investors/overview",
  "structured_data": [
    {
      "section_name": "Press Releases",
      "links": [
        {
          "title": "Vistagen to Present at the Stifel 2024 Healthcare Conference",
          "url": "https://www.vistagen.com/news-releases/news-release-details/vistagen-present-stifel-2024-healthcare-conference",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![](/system/files-encrypted/nasdaq_kms/inline-images/news.jpg)\n\n# We’re on the pulse of innovations in mental health treatment. Follow our journey.\n\n## Press Release\n\n### \n\nVistagen to Present at the Stifel 2024 Healthcare Conference\n\nNovember 14, 2024 \n\n[PDF Version](/node/13901/pdf)\n\nSOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Nov. 14, 2024-- Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. \n\n**Stifel 2024 Healthcare Conference**\n\n  * Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35 p.m. Eastern Time. \n\n\n\nA webcast will be accessible through the “Events” page in the “Investors” section of the Company’s website at [www.Vistagen.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.Vistagen.com&esheet=54152768&newsitemid=20241114792150&lan=en-US&anchor=www.Vistagen.com&index=1&md5=1e47acf732bc470a2e7c6e456970a3f6). Investors interested in arranging a one-on-one meeting during the conference should contact their Stifel representative. \n\n**About Vistagen**\n\nHeadquartered in South San Francisco, CA, Vistagen (Nasdaq: VTGN) is a late clinical-stage company leveraging its pioneering neuroscience and deep understanding of nose-to-brain neurocircuitry to develop and commercialize a broad and diverse pipeline of intranasal product candidates called pherines. Each pherine product candidate in Vistagen’s neuroscience pipeline is designed to rapidly activate olfactory system and brain neurocircuitry to achieve desired therapeutic benefits and differentiated safety without requiring systemic absorption or binding to neurons in the brain. Vistagen’s neuroscience pipeline also includes an oral prodrug, AV-101, with potential to impact certain neurological conditions involving the NMDA receptor. Vistagen is passionate about developing transformative treatment options to improve the lives of individuals underserved by the current standard of care for multiple highly prevalent disorders, including social anxiety disorder, major depressive disorder, and vasomotor symptoms (hot flashes) associated with menopause. Connect at [www.Vistagen.com](https://cts.businesswire.com/ct/CT?id=smartlink&url=http%3A%2F%2Fwww.Vistagen.com&esheet=54152768&newsitemid=20241114792150&lan=en-US&anchor=www.Vistagen.com&index=2&md5=cfa53d26c17ecc579383a2b6b9f6ff26). \n\n![News Release image](https://cts.businesswire.com/ct/CT?id=bwnews&sty=20241114792150r1&sid=acqr8&distro=nx&lang=en)\n\nView source version on [businesswire.com](http://businesswire.com): <https://www.businesswire.com/news/home/20241114792150/en/>\n\nInvestors: Mark A. McPartland Vistagen Therapeutics markmcp@vistagen.com\n\nMedia: Caren Scannell Vistagen Therapeutics cscannell@vistagen.com\n\nSource: Vistagen\n"
        }
      ]
    },
    {
      "section_name": "SEC Filings",
      "links": [
        {
          "title": "10-Q",
          "url": "https://www.vistagen.com/sec-filings/sec-filing/10-q/0001411685-24-000048",
          "content": "[ Skip to main navigation ](#main-menu)\n\n![\"IR Home Page Banner\"](/system/files-encrypted/nasdaq_kms/inline-images/Investors_Page_Headline_Image.jpg)\n\n# Bold opportunities to change the course of mental health care.\n\n## SEC Filing\n\n### Document Details\n\nForm\n\n[ 10-Q ](/node/13871/html)\n\nFiling Date\n\nNov 7, 2024\n\nDocument Date\n\nSep 30, 2024\n\nForm Description\n\nQuarterly report which provides a continuing view of a company's financial position\n\nFiling Group\n\nQuarterly Filings\n\nCompany\n\nVistagen Therapeutics, Inc\n\nIssuer\n\nVistaGen Therapeutics, Inc.\n\n### Filing Formats\n\n[iXBRL](/node/13871/ixbrl-viewer)\n\n[View HTML](/node/13871/html)\n\n[Download PDF](/static-files/ec00856c-198a-478e-88d7-bfe8e257cb3d \"0001411685-24-000048.pdf\")\n\n[Download DOC](/static-files/2fbd1daa-0fc4-40dd-a2d7-ee6dcd1acbaa \"0001411685-24-000048.rtf\")\n\n[Download XLS](/static-files/a07424ab-1fbc-4407-ae3f-50e5265d99aa \"0001411685-24-000048.xls\")\n\n### XBRL\n\n[XBRL Viewer](/node/13871/xbrl-viewer)\n\n[EX-101.SCH - XBRL TAXONOMY EXTENSION SCHEMA](/static-files/b9876771-69ef-4340-a8b6-eead5b1daf69 \"0001411685-24-000048-ex-101-sch---xbrl-taxonomy-extension-schema.xsd\")\n\n[EX-101.CAL - XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT](/static-files/925cbbc7-20cd-491f-91ca-0d55b7b2e6ff \"0001411685-24-000048-ex-101-cal---xbrl-taxonomy-extension-calculation-linkbase-document.xml\")\n\n[EX-101.DEF - XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT](/static-files/ef033ace-84ae-4b5a-89f8-e8a5d126a682 \"0001411685-24-000048-ex-101-def---xbrl-taxonomy-extension-definition-linkbase-document.xml\")\n\n[EX-101.LAB - XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT](/static-files/31c88535-4a88-4409-8d53-3385b2abe84e \"0001411685-24-000048-ex-101-lab---xbrl-taxonomy-extension-label-linkbase-document.xml\")\n\n[EX-101.PRE - XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT](/static-files/4a8eb237-cbad-47cb-b30e-9cc62fdf7196 \"0001411685-24-000048-ex-101-pre---xbrl-taxonomy-extension-presentation-linkbase-document.xml\")\n\n[XML - XBRL INSTANCE DOCUMENT](/static-files/dd6c35bc-77f3-4504-b2a4-f0577fd514c7 \"0001411685-24-000048-xml---xbrl-instance-document.xml\")\n\nAnnual Reports\n\nAnnual reports provide a comprehensive overview of the company for the past year\n\n[View Reports](/investors/sec-filings/annual-reports)\n\nQuarterly Reports\n\nQuarterly reports provide a continuing view of the company's financial position\n\n[View Reports](/investors/sec-filings/quarterly-reports)\n\nSEC Filings\n\nStatement of changes in beneficial ownership of securities\n\n[View Filings](/investors/sec-filings/section-16-filings)\n\n[ ![Key Contact Info](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/contact-ir-static.svg) ![Key Contact Info](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/contact-ir-rollover.svg) Key Contact Info ](/investors/investors-tools/key-contact-info)\n\n[ ![FAQ](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/faq-static.svg) ![FAQ](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/faq-rollover.svg) FAQ ](/investors/investors-tools/faqs)\n\n[ ![Presentations](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/tearsheet-static.svg) ![Presentations](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/tearsheet-rollover.svg) Presentations ](/presentations)\n\n[ ![Email Alerts](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/alerts-static.svg) ![Email Alerts](/sites/g/files/knoqqb89326/themes/site/nir_pid5382/dist/images/icons/alerts-rollover.svg) Email Alerts ](/investors/investors-tools/email-alerts)\n"
        }
      ]
    }
  ]
}